Several factors—such as bone pain and year of metastasis—are predictive of skeletal-related events (SREs) among patients being treated for bone metastatic castration-resistant prostate cancer (mCRPC), according to a study published in Cancer.1

Researchers evaluated data from 233 patients with non-metastatic CRPC who developed bone metastases during follow-up to determine factors predictive of SREs. Patients were a median age of 75 years at time of diagnosis.

At a median follow-up of 7.8 months, the researchers noted 88 patients who had an SRE.

A more recent year of metastasis, prostate-specific antigen doubling time of at least 9 months as opposed to less than 9 months, as well as bone pain were associated with SRE risk upon univariable analysis.

Year of metastasis, a biopsy Gleason score of at least 7, radiotherapy as the primary localized treatment, and bone pain were associated with SRE risk upon multivariable analysis.

RELATED: GATA2 in Prostate Cancer: A Promising Biomarker

“If confirmed, future trials should focus on prolonging life and reducing SRE risk in patients with mCRPC with bone pain,” the authors concluded.

Reference

  1. Klaassen Z, Howard LE, de Hoedt A, et al. Factors predicting skeletal-related events in patients with bone metastatic castration-resistant prostate cancer. Cancer. 2016 27 Dec. doi: 10.1002/cncr.30505 [Epub ahead of print]